pamidronate

出典: meddic

パミドロン酸

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/06/01 16:35:48」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia.
  • Leblicq C, Laverdière C, Décarie JC, Delisle JF, Isler MH, Moghrabi A, Chabot G, Alos N.SourceEndocrinology Service and Research Center, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada.
  • Pediatric blood & cancer.Pediatr Blood Cancer.2013 May;60(5):741-7. doi: 10.1002/pbc.24313. Epub 2012 Sep 21.
  • BACKGROUND: Osteonecrosis (ON) is a severe complication of acute lymphoblastic leukemia (ALL) treatments. Recent studies suggest that bisphosphonates might reduce pain and loss of motor function in patients with ON. We assessed the effects of pamidronate compared to standard care in patients with sy
  • PMID 23002054
  • Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.
  • Baroncelli GI, Vierucci F, Bertelloni S, Erba P, Zampollo E, Giuca MR.SourcePediatric Unit I, Department of Obstetrics, Gynecology and Pediatrics, University-Hospital, Via Roma 67, 56126, Pisa, Italy, g.baroncelli@med.unipi.it.
  • Journal of bone and mineral metabolism.J Bone Miner Metab.2013 Apr 3. [Epub ahead of print]
  • Although spontaneous remission occurs in patients with idiopathic juvenile osteoporosis (IJO), permanent bone deformities may occur. The effects of long-term pamidronate treatment on clinical findings, bone mineral status, and fracture rate were evaluated. Nine patients (age 9.8 ± 1.1 years, 7 m
  • PMID 23549954
  • Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
  • Cha YJ, Lee YJ.AbstractObjective: Using retrospective prescription analysis, this study aimed to investigate the risk factors for renal impairment among adult solid tumor and multiple myeloma patients who have received zoledronic acid injections in a teaching hospital over the last 4 years. Methods: We examined solid tumor and multiple myeloma patients who had received at least 1 zoledronic acid injection in a teaching hospital in Seoul with at least 2,000 beds over the 4 years between January 2008 and December 2011. The injection histories and serum creatinine levels of these patients were included in the analysis. Patients who developed renal impairment subsequent to zoledronic acid injection were identified, and the risk factors were statistically analyzed. Results: In only 1 case was zoledronic acid injection reduced as directed by the creatinine clearance guidelines. Four patients whose creatinine clearance was less than 30 ml/min were injected with zoledronic acid even though its use is contraindicated in this situation. Of the 338 research subjects, 26 developed renal impairment. The following were confirmed to be statistically significant (p < 0.05) risk factors for the development of renal impairment: serum creatinine (at first injection) of greater than 1.4 mg/dl, diabetes, hypertension, thalidomide prescription, multiple myeloma, and previous pamidronate usage. Conclusions: Based on the results of this study, renal monitoring is necessary following zoledronic acid injection. In addition, for patients with renal impairment risk factors, a risk-benefit analysis must be performed before zoledronic acid is administered, and it must be administered at an appropriate dose according to the level of renal function.
  • International journal of clinical pharmacology and therapeutics.Int J Clin Pharmacol Ther.2013 Apr;51(4):274-82. doi: 10.5414/CP201823.
  • Objective: Using retrospective prescription analysis, this study aimed to investigate the risk factors for renal impairment among adult solid tumor and multiple myeloma patients who have received zoledronic acid injections in a teaching hospital over the last 4 years. Methods: We examined solid tumo
  • PMID 23357846

和文文献

  • 若年者のびまん性硬化性下顎骨骨髄炎にパミドロネートが著効した1例
  • びまん性硬化性下顎骨骨髄炎として初発しビスフォスフォネートが著効したSAPHO症候群の1例
  • Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis : comparison with untreated patients
  • Journal of bone and mineral metabolism 31(5), 533-543, 2013-09-30
  • NAID 10031201687

関連リンク

Information on how bisphosphonates are used to help cancer patients. ... Pamidronate is a type of drug called a bisphosphonate. It’s used to treat osteoporosis. This is a condition when the bones become thinner or weaker.
Pamidronate official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. ... Excretion After administration of 30, 60, and 90 mg of Pamidronate disodium over ...

関連画像

 Pamidronate - Inj Pamidronate Disodium forPamidronate Disodium for Injectionstructural formula pamidronate disodiumPamidronate Disodium for InjectionModeling the benefits of pamidronate in Pamidronate Disodium Injection


★リンクテーブル★
リンク元ビスホスフォネート」「パミドロン酸」「pamidronic acid
拡張検索pamidronate disodium

ビスホスフォネート」

  [★]

bisphosphonate
ビスフォスフォネートビスホスホネートビスホスホン酸ビスホスホネート製剤
骨粗鬆症
  • 第1世代
  • 第2世代
  • 第3世代




パミドロン酸」

  [★]

pamidronatepamidronic acid
パミドロネートパミドロン酸二ナトリウム pamidronate disodium
アレディア Aredia

他に分類されない代謝性医薬品




pamidronic acid」

  [★]

pamidronatepamidronate disodium


pamidronate disodium」

  [★] パミドロン酸パミドロン酸二ナトリウム




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡